Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 4 years of Other Operating Expenses data on file, last reported at -$373354.0 in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$373354.0, up 67.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$582432.0 (up 50.0% YoY), and the FY2025 annual result was -$1.4 million, changed N/A from the prior year.
• Other Operating Expenses declined to -$373354.0 in Q1 2026 per IKT's latest filing, from $642169.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $642169.0 in Q4 2025 and troughed at -$10.6 million in Q4 2023.
• A 3-year average of -$2.1 million and a median of -$433090.5 in 2025 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 67.95% in 2026 and fell as far as 67.95% in 2026.
• A 3-year view of Other Operating Expenses shows it stood at -$10.6 million in 2023, then surged by 106.07% to $642169.0 in 2025, then plunged by 158.14% to -$373354.0 in 2026.
• Business Quant data shows IKT's Other Operating Expenses at -$373354.0 in Q1 2026, $642169.0 in Q4 2025, and -$492827.0 in Q3 2025.